Atkins MB et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq trial—ECOG-ACRIN EA6134. J Clin Oncol 2023;41(2):186-97. Abstract
Carlino MS et al. Minimal residual disease by circulating tumor DNA as biomarker of recurrence-free survival in resected high-risk melanoma patients treated with mRNA-4157 (v940), a personalized cancer vaccine, and pembrolizumab. ASCO 2023;Abstract LBA9515.
Dixon-Douglas JR et al. Triplet therapy in melanoma – combined BRAF/MEK inhibitors and anti-PD-(L)1 antibodies. Curr Oncol Rep 2022;24(8):1071-9. Abstract
Drummer R et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383(12):1139-48. Abstract
Eroglu Z et al. Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAFV600-mutant metastatic melanoma (MM) (CTEP P9466). ASCO 2023;Abstract 9511.
Garbe C et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med 2023;29(6):1310-2. Abstract
Gonzalez M et al. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II. ASCO 2023;Abstract TPS9610.
Hamid O et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. ASCO 2023;Abstract 9501.
Hodi SF et al. Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067. ASCO 2023;Abstract 9542.
Hodi SF et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. ASCO 2022;Abstract 9522.
Khattak A et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. ASCO 2023;Abstract LBA9503.
Lee R et al. Adjuvant therapy for stage II melanoma: The need for further studies. Eur J Cancer 2023;189:112914. Abstract
Long GV et al. Cutaneous melanoma. Lancet 2023;402(10400):485-502. Abstract
Long GV et al. Neoadjuvant checkpoint immunotherapy and melanoma: The time is now. J Clin Oncol 2023;41(17):3236-48. Abstract
Long GV et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): Distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2022;23(11):1378-88. Abstract
Long GV et al. Five-year overall survival from the anti-PD1 brain collaboration (ABC study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). ASCO 2021;Abstract 9508.
Luke JJ et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final distant metastasis-free survival analysis in the phase 2 KEYNOTE-716 study. ASCO 2023;Abstract LBA9505.
Patel SP et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388(9):813-23. Abstract
Robert C et al. Seven-year follow-up of the phase III KEYNOTE-006 study: Pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol 2023;[Online ahead of print]. Abstract
Rohaan MW et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 2022;387(23):2113-25. Abstract
Schadendorf D et al. Adjuvant dabrafenib + trametinib (D + T) vs placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant-metastases-free survival (DMFS) analysis of COMBI-AD. ASCO 2022;Abstract 9563.
Shteinman ER et al. Molecular and clinical correlates of HER3 expression highlights its potential roles as a therapeutic target in melanoma. Pathology 2023;55(5):629-36. Abstract
Simpson RC et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat Revs 2023;[Online ahead of print]. Abstract
Spira A et al. Trials in progress: A global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma. AACR 2023;Abstract CT032.
Tawbi HA et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. ASCO 2023;Abstract 9502.
Tawbi HA et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): Final results of an open-label, multicentre, phase 2 study. Lancet Oncol 2021;22(12):1692-704. Abstract
Vellano CP et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 2022;606(7915):797-803. Abstract